A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Rituximab-Arrx (Riabni)

Rituximab-Arrx targets CD20-positive cells to treat certain lymphomas and autoimmune conditions.

First FDA approval2021-01-06
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$11.6M in CY2024 Part D spend2K claims · 596 beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Rituximab-Arrx used for?

Rituximab-Arrx targets CD20-positive cells to treat certain lymphomas and autoimmune conditions.

Is there a generic for Rituximab-Arrx?

No. Rituximab-Arrx is brand-only with no generic equivalents currently in market.

How much does my plan pay for Rituximab-Arrx?

NADAC pricing data not currently available for this drug.

Is Rituximab-Arrx on the FDA shortage list?

No. Rituximab-Arrx is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

CD20-directed Cytolytic Antibody6 alternatives in D1
01
Obinutuzumab
Brand: Gazyva
Lowest NADAC
0Generic mfrs
$15.0MCY24 Part D spend
Compare →
02
Ocrelizumab
Brand: OCREVUS
Lowest NADAC
0Generic mfrs
$319.4MCY24 Part D spend
Compare →
03
Ofatumumab
Brand: ARZERRA
$24459.32Lowest NADAC
0Generic mfrs
$975.4MCY24 Part D spend
Compare →
04
Rituximab
Brand: Rituxan
Lowest NADAC
0Generic mfrs
$61.6MCY24 Part D spend
Compare →
05
Rituximab-Abbs
Brand: Truxima
Lowest NADAC
0Generic mfrs
$36.2MCY24 Part D spend
Compare →
06
Rituximab-Pvvr
Brand: Ruxience
Lowest NADAC
0Generic mfrs
$42.1MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.